drug_type
RELEVANT_DRUG
intervention_type
Biological (adoptive cellular immunotherapy)
drug_description
Ex vivo generated and expanded autologous cytotoxic T cells engineered by selection/expansion to recognize TAA peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I, administered as adoptive cellular immunotherapy to eradicate residual lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Cytotoxic
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous cytotoxic T lymphocytes are generated and expanded ex vivo for endogenous TCR specificity to tumor‑associated antigen peptides (NY-ESO-1, MAGEA4, PRAME, Survivin, SSX) presented on HLA class I. After infusion, these CTLs recognize HLA-restricted TAA on lymphoma cells and induce targeted killing via perforin/granzyme release and cytokine-mediated effector functions to eradicate residual disease.
drug_name
Autologous tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes (CTLs)
nct_id_drug_ref
NCT05134740